1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evotec : expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach

01/11/2022 | 01:48am EDT

NEWS RELEASE, 11 JANUARY 2022

EVOTEC EXPANDS NEUROSCIENCE COLLABORATION WITH BRISTOL MYERS SQUIBB TO INCLUDE NEW TARGETED PROTEIN DEGRADATION APPROACH

  • EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS
  • EVOTEC RECEIVES PAYMENTS OF IN TOTAL US$ 15 M FROM BRISTOL MYERS SQUIBB

Hamburg, Germany, 11 January 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;

NASDAQ: EVO) announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb (NYSE:BMY) with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer's through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb.

Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Our

collaboration with Bristol Myers Squibb in the field of neurodegenerative disease continues to be highly productive. Many neurodegenerative diseases are driven by disease-causing proteins which have proven to be elusive to traditional drug discovery approaches. We are committed to continuously explore novel drug targeting mechanisms and modalities and are delighted to have a strong partner with BMS in this endeavour."

The neurodegeneration collaboration between Evotec and Bristol Myers Squibb was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-termmanagement of the patients' symptoms despite a huge unmet medical

For further information, please contact: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing,

gabriele.hansen@evotec.com, T. +49.(0)40.560 81-255, F. +49.(0)40.560 81-333, www.evotec.com

NEWS RELEASE

need for drugs that have the potential to slow down or reverse disease progression.

The collaboration leverages Evotec's industrialised iPSC platform using patient-

derived disease models, which is one of the largest and most sophisticated platforms

in the industry.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's

multimodality platform comprises a unique combination of innovative technologies, data and science

for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-drivenR&D Autobahn to Cures" for proprietary projects and

within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world- leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more

than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer

highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.comand follow us on Twitter @Evotecand LinkedIn.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and

variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward- looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of

Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's

expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

2

Disclaimer

Evotec SE published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 06:47:05 UTC.


ę Publicnow 2022
All news about EVOTEC SE
08:34aEvotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
AQ
04:14aEVOTEC : Deutsche Bank maintains a Buy rating
MD
05/17TRANSCRIPT : Evotec SE, Sernova Corp. - M&A Call
CI
05/17Nasdaq-Listed Evotec and Sernova Detail Strategic Partnership For Therapy to Advance 'F..
MT
05/17Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based ..
AQ
05/17EVOTEC : RBC reaffirms its Buy rating
MD
05/17Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell re..
EQ
05/17Evotec SE and Sernova Corp Announces Partnership in the Field of Diabetes
CI
05/17Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evot..
CI
05/16EVOTEC : Receives a Buy rating from Berenberg
MD
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2022 682 M 718 M 718 M
Net income 2022 -10,5 M -11,1 M -11,1 M
Net cash 2022 86,0 M 90,6 M 90,6 M
P/E ratio 2022 -444x
Yield 2022 -
Capitalization 4 395 M 4 629 M 4 629 M
EV / Sales 2022 6,32x
EV / Sales 2023 5,34x
Nbr of Employees 4 354
Free-Float 87,7%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 24,87 €
Average target price 36,44 €
Spread / Average Target 46,5%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris L÷w-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-41.48%4 629
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002